California has removed prior authorization requirements for medically necessary direct-acting antiviral drugs used to treat hepatitis C. Gov. Gavin Newsom signed the legislation Sept. 27. It bars health care service plans and health insurers from subjecting medically necessary direct-acting antiviral…

Health systems are facing a hard question: as site-of-care pressure pushes more infusion volume away from the hospital outpatient department (HOPD), how do they keep appropriate care inside the system? The infusion market keeps growing — spending is projected to…

A September 2026 American Medical Association Policy Research Perspective analyzed Decision Resources Group data on PBM and insurer market shares from 2022 to 2024. Together, the four largest PBMs controlled 75% of the national market, up from 70% in 2022.…

It’s the end of the world as we know it; panic and mass hysteria. That is roughly the tone of recent coverage of the pharmacy changes arriving in 2027, and it is worth turning the volume down, because the truth…

The FDA has approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. Emcitate is the first FDA-approved treatment for peripheral thyrotoxicosis in patients with the rare genetic disorder, according to a Sept.…

Section 232 tariffs on patented pharmaceutical products and associated pharmaceutical ingredients took effect Sept. 29 for companies not covered by the earlier July 31 implementation date. The tariffs follow a Commerce Department investigation that found U.S. dependence on imported pharmaceuticals…

Orange, Calif.-based UCI Health has appointed Melanie Joe, PharmD, vice president and system chief pharmacy officer. Dr. Joe is responsible for developing the strategic vision for UCI Health Pharmaceutical Services, according to a LinkedIn post from the UC Irvine School…

A September white paper from Pioneer Institute and CancerCare compared nearly 4,000 hospitals using CMS cost report data linked to HRSA’s 340B covered-entity records to examine differences in patient assistance measures between 340B and non-340B hospitals. Here are six things…

The Trump administration is developing an initiative aimed at moving production of 86 essential medicines to the U.S. within 18 months, according to a Sept. 25 Bloomberg report. Under the initiative, the Office of Management and Budget would solicit proposals…

Inventia Healthcare Limited has recalled 13,567 bottles of chlorthalidone tablets after the product failed dissolution specifications. The voluntary recall covers Chlorthalidone Tablets, USP, 25 milligram, packaged in 100-tablet bottles and distributed nationwide, according to an FDA enforcement report. The affected…